H Lundbeck (Denmark) Today
| HLUN-B Stock | 44.00 0.04 0.09% |
Performance0 of 100
| Odds Of DistressLess than 9
|
H Lundbeck is trading at 44.00 as of the 2nd of December 2024, a 0.09 percent up since the beginning of the trading day. The stock's open price was 43.96. H Lundbeck has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for H Lundbeck AS are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of December 2023 and ending today, the 2nd of December 2024. Click here to learn more.
Moving together with HLUN-B Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
HLUN-B Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. H Lundbeck's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding H Lundbeck or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers-Specialty & Generic, Healthcare (View all Sectors) |
H Lundbeck AS (HLUN-B) is traded on Copenhagen Exchange in Denmark and employs 5,450 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 29.29 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate H Lundbeck's market, we take the total number of its shares issued and multiply it by H Lundbeck's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. H Lundbeck AS operates under Healthcare sector and is part of Drug Manufacturers-Specialty & Generic industry. The entity has 794.27 M outstanding shares.
Check H Lundbeck Probability Of Bankruptcy
Ownership AllocationH Lundbeck AS has a total of 794.27 Million outstanding shares. The majority of H Lundbeck AS outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in H Lundbeck to benefit from reduced commissions. Hence, third-party entities are subject to a different set of regulations than regular investors in H Lundbeck AS. Please pay attention to any change in the institutional holdings of H Lundbeck AS as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check HLUN-B Ownership Details
H Lundbeck AS Risk Profiles
Although H Lundbeck's alpha and beta are two of the key measurements used to evaluate H Lundbeck's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.23 | |||
| Standard Deviation | 1.66 | |||
| Variance | 2.76 | |||
| Risk Adjusted Performance | (0.05) |
HLUN-B Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in H Lundbeck without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Breakdown Now
Idea BreakdownAnalyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
| All Next | Launch Module |
H Lundbeck Corporate Management
Elected by the shareholders, the H Lundbeck's board of directors comprises two types of representatives: H Lundbeck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HLUN-B. The board's role is to monitor H Lundbeck's management team and ensure that shareholders' interests are well served. H Lundbeck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, H Lundbeck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elise Hauge | Ex Communication | Profile | |
| Keld Jorgensen | Exec Devel | Profile | |
| Palle Olesen | Chief Relations | Profile | |
| Joerg Hornstein | CFO Functions | Profile | |
| Ole Chrintz | VP Markets | Profile | |
| Jacob Tolstrup | Ex Officer | Profile | |
| Deborah MD | Pres CEO | Profile |
Other Information on Investing in HLUN-B Stock
H Lundbeck financial ratios help investors to determine whether HLUN-B Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLUN-B with respect to the benefits of owning H Lundbeck security.